Trump-backed plan could fast-track psychedelic therapies — here’s what to know

President Trump signed an executive order to fast-track research, funding, and potential FDA approval of psychedelic drugs like psilocybin and MDMA for treating PTSD, depression, and addiction. Supporters, including veterans' advocates and medical analysts, highlight potential benefits for treatment-resistant cases, while critics warn about insufficient safety and efficacy evidence.